Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alocyte
- Development stage
- Phase 1
- Lead developer
- Alimorad Farshchian
- Modality
- Cell Therapies
- Administration
- Intraarticular
01
Overview
**Alocyte** is an investigational, minimally manipulated human umbilical cord blood-derived cellular product comprising cord blood plasma and cord blood mononuclear cells. It is being evaluated as a locally administered regenerative treatment for chronic facetogenic back pain through intra-articular injection into affected spinal facet joints. The registered Phase 1 dose-escalation study describes intended pro-angiogenic, immunomodulatory, anti-inflammatory, metabolic-supportive, and tissue-repair activities, but no single validated molecular target or definitive clinical mechanism has been established. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05909709))
- Brand names
- Alocyte
- Other names
- Alocyte
Beyond the preview
Go deeper on Alocyte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alocyte.